No Data
No Data
Shanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025
SH PHARMA (601607.SH): Isosorbide dinitrate injection has passed the consistency evaluation of generic drugs.
On January 2, Gelonghui reported that SH PHARMA (601607.SH) announced that its wholly-owned subsidiary, Shanghai SH PHARMA First Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as 'SH PHARMA First Biochemical'), received the 'Pharmaceutical Supplement Application Approval Notice' (Notice No: 2024B05558) issued by the National Medical Products Administration regarding Isosorbide Dinitrate Injection (hereinafter referred to as 'the Pharmaceutical'), which has passed the consistency evaluation of quality and efficacy for generic drugs.
Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal
Hutchmed (China) plans to sell a total of 45% equity in Shanghai Hutchmed.
Hutchmed (China) (00013) announced that on December 31, 2024, the seller, Shanghai Hutchmed Pharmaceutical Investment (Hong Kong) Limited (a wholly-owned subsidiary of the company), entered into a share purchase agreement with Jinpu Jianfu for the sale of shares pending purchase at a total purchase price of RMB 3.483 billion (approximately USD 0.473 billion), representing 35% of the equity of Shanghai Hutchmed; and entered into a share purchase agreement with SH PHARMA for the sale of shares pending purchase at a total purchase price of RMB 0.995 billion (approximately USD 0.135 billion), representing 10% of the equity of Shanghai Hutchmed.
HUTCHMED to Divest 45% Stake in JV With Shanghai Pharma
SH PHARMA (601607.SH): Termination of projects I001-B (USA), I022 (USA), C012 (USA).
On January 1, Gelonghui reported that SH PHARMA (601607.SH) announced the decision to terminate the clinical trials and subsequent development of three research and development projects: I001-B (USA), I022 (USA), and C012 (USA). This decision was made after a comprehensive assessment of factors such as the future market value of the R&D projects, business synergy, and subsequent development investment. Among them, I001-B (USA) and I022 (USA) are in Phase II clinical trials in the USA, while C012 (USA) has received approval from the USA Food and Drug Administration (referred to as "FDA").
See the daily top gainer.